Objective: This study was conducted to compare overactive bladder (OAB) prevalence among people greater than 60 years of age who intake various doses of caffeine, as well as those who abstain from caffeine. Patients and Methods: A randomized observational study was carried out in Vladivostok Gerontological Hospital. A total of 1,098 retired people greater than 60 years of age (659 women and 439 men, average age 67.1 years) took part in the study. They were admitted to the in-patient department with the purpose of annual physical examination performed in accordance with the order of the Ministry of Public Health of the Russian Federation. People over age 60, who at the moment of examination were in satisfactory health condition, were included into the study. People in which OAB had been detected or who used to take antimuscarinic were excluded from the study. Assessment tools for examining the patients' lower urinary tract condition were as follows: OAB-q SF, urination diaries, and uroflowmetry. Results: In the course of the experiment conducted, we found that 1/3 of people, both men and women greater than 60 years of age, who did not previously seek medical advice due to urination troubles, had symptoms of detrusor overactivity. These symptoms were moderate and did not bother patients too much in most cases (63.4%). It was also found that most patients consumed no more than 300mg caffeine with beverages per day, with 30% and 10% of patients suffering from OAB or severe detrusor overactivity, respectively. At the same time, almost 50% of patients taking more than 300 mg of caffeine per day suffer from OAB. Conclusion:48.1% of people over 60 years of age suffering from overactive detrusor symptoms consume greater than 300 mg caffeine daily, which is significantly higher than that of their peers who do not intake excessive amounts of caffeine.

Keywords:
Antimuscarinic, Elderly patients, Overactive bladder
1.
Lugo Salcedo F, Sánchez Borrego R: Assessment of female prevalence of overactive bladder (OAB) in Barcelona using a self-administered screening questionnaire: the Cuestionario de Autoevaluación del Control de la Vejiga (CACV). Int Urogynecol J 2013; 24:1559-1566.
2.
Wen JG, Li JS, Wang ZM, Huang CX, Shang XP, Su ZQ, Lu YT, Suo ZH, Wang Y, Qin GJ, Zhang WX, Heesakkers JP: The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourol Urodyn 2014;33:387-391.
3.
Diamond P, Hassonah S, Alarab M, Lovatsis D, Drutz HP: The prevalence of detrusor overactivity amongst patients with symptoms of overactive bladder: a retrospective cohort study. Int Urogynecol J 2012;23:1577-1580.
4.
Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, Chen CI, Quentin Clemens J: The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn 2013;32:230-237.
5.
Heesakkers J, Cruz F, Igawa Y, Kocjancic E: Overactive bladder: pathophysiology, diagnostics, and therapies. Adv Urol 2011;2011:863504.
6.
Wagg AS , Cardozo L, Chapple C, De Ridder D, Kelleher C, Kirby M, Milsom I, Vierhout M: Overactive bladder syndrome in older people. BJU Int 2007;99:502-509.
7.
Andersson KE: Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011;59:377-386.
8.
Andersson KE: Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol 2011;202:319-344.
9.
Igawa Y, Aizawa N, Homma Y: Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 2010;51:811-818.
10.
Kanai AJ: Afferent mechanism in the urinary tract. Handb Exp Pharmacol 2011;202:171-205.
11.
de Boer TA, Salvatore S, Cardozo L, Chapple C, Kelleher C, van Kerrebroeck P, Kirby MG, Koelbl H, Espuna-Pons M, Milsom I, Tubaro A, Wagg A, Vierhout ME: Pelvic organ prolapse and overactive bladder. Neurourol Urodyn 2010;29:30-39.
12.
Tyagi P, Tyagi V, Qu X, Lin HT, Kuo HC, Chuang YC, Chancellor M: Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly population. Int Urol Nephrol 2014;46:871-877.
13.
Zorba OÜ, Kirba S, Uzun H, Cetinkaya M, Önem K, Rifaio lu MM: Overactive bladder and pontine reticular formation. Urol Int 2013;91:417-422.
14.
Sakakibara R, Panicker J, Fowler CJ, Tateno F, Kishi M, Tsuyusaki Y, Yamanishi T, Uchiyama T, Yamamoto T, Yano M: Is overactive bladder a brain disease? The pathophysiological role of cerebral white matter in the elderly. Int J Urol 2014;21:33-38.
15.
Meeusen R, Roelands B, Spriet LL: Caffeine, exercise and the brain. Nestle Nutr Inst Workshop Ser 2013;76:1-12.
16.
Haller S, Montandon M, Rodriguez C: Acute caffeine administration effect on brain activation patterns in mild cognitive impairment. J Alzheimers Dis 2014;41:101-112.
17.
Lohsiriwat S, Hirunsai M, Chaiyaprasithi B: Effect of caffeine on bladder function in patients with overactive bladder symptoms. Urol Ann 2011;3:14-18.
18.
Kershen R, Mann-Gow T, Yared J, Stromberg I, Zvara P: Caffeine ingestion causes detrusor overactivity and afferent nerve excitation in mice. J Urol 2012;188:1986-1992.
19.
Maserejian NN, Wager CG, Giovannucci EL, Curto TM, McVary KT, McKinlay JB: Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women. Am J Epidemiol 2013;177:1399-1410.
20.
Wells MJ, Jamieson K, Markham TC, Green SM, Fader MJ: The effect of caffeinated versus decaffeinated drinks on overactive bladder: a double-blind, randomized, crossover study. J Wound Ostomy Continence Nurs 2014;41:371-378.
21.
Chakravarthy V, Tolbert M, Garcia C, Miller J: Overactive bladder and caffeine: comparing women with and without mental health diagnoses. Int J Urol Nurs 2010;4:13-21.
22.
Coyne KS, Zyczynski T, Margolis MK, Elinoff V, Roberts RG: Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005;22:381-394.
23.
Coyne KS, Margolis MK, Bavendam T, Roberts R, Elinoff V: Validation of a 3-item OAB awareness tool. Int J Clin Pract 2011;65:219-224.
24.
Parsons M, Amundsen CL, Cardozo L, Vella M, Webster GD, Coats AC: Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence. Neurourol Urodyn 2007;26:800-806.
25.
Amundsen CL, Parsons M, Cardozo L, Vella M, Webster GD, Coats AC: Bladder diary volume per void measurements in detrusor overactivity. J Urol 2006;176:2530-2534.
26.
Schröder A, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Tubaro A, Thüroff JW: Guidelines on Urinary Incontinence. European Association of Urology, 2009, S52.
27.
Singh G, Lucas M, Dolan L, Knight S, Ramage C, Hobson PT: Minimum standards for urodynamic practice in the UK. Neurourol Urodyn 2010;29:1365-1372.
28.
Dmochowski RR, Larson-Peters A, Aronstein WS, Seifu Y: Efficacy of Darifenacin in patients with varying baseline symptom severity. UroToday Int J 2009;2(3).
29.
Wagg A: Treating overactive bladder in the elderly. Can Urol Assoc J 2011;5(5 Suppl 2):S149-S151.
30.
Cano-Marquina A, Tarín JJ, Cano A: The impact of coffee on health. Maturitas 2013;75:7-21.
31.
Juliano LM, Griffiths RR: Caffeine; in Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds.). Substance Abuse: A Comprehensive Textbook, ed 4. Baltimore, Lippincott, Williams, & Wilkins, 2005, pp403-421.
32.
National Institute on Alcohol Abuse and Alcoholism No.16 PH 315 April 1992.
33.
Robinson D, Giarenis I, Cardozo L: You are what you eat: the impact of diet on overactive bladder and lower urinary tract symptoms. Maturitas 2014;79:8-13.
34.
Selo-Ojeme D, Pathak S, Aziz A, Odumosu M: Fluid and caffeine intake and urinary symptoms in the UK. Int J Gynaecol Obstet 2013;122:159-160.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.